Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 66% of modeled bridge. Strengths: Bed Count. Risks: Occupancy Rate. Risk-adjusted uplift: $1.2M (vs $1.8M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $689K | $689K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $663K | $19K | $682K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $106K | $313K | $419K | $1.3M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $22K | $22K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 55.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $172K | $344K | $516K | $689K | $689K | $689K | $689K |
| Denial Rate Reduction | $0 | $170K | $341K | $511K | $682K | $682K | $682K | $682K |
| A/R Days Reduction | $0 | $140K | $279K | $419K | $419K | $419K | $419K | $419K |
| Clean Claim Rate | $0 | $11K | $22K | $22K | $22K | $22K | $22K | $22K |
| Cumulative | $0 | $493K | $987K | $1.5M | $1.8M | $1.8M | $1.8M | $1.8M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.8M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 89% / 24.1x | 93% / 27.1x | 98% / 30.2x | 100% / 31.7x | 101% / 33.2x |
| 9.0x | 84% / 21.1x | 88% / 23.8x | 93% / 26.4x | 94% / 27.8x | 96% / 29.1x |
| 10.0x | 79% / 18.6x | 84% / 21.1x | 88% / 23.5x | 90% / 24.7x | 92% / 25.9x |
| 11.0x | 75% / 16.6x | 80% / 18.8x | 84% / 21.1x | 86% / 22.1x | 88% / 23.3x |
| 12.0x | 72% / 15.0x | 76% / 17.0x | 80% / 19.0x | 82% / 20.0x | 84% / 21.1x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 64% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.4x, adding 6.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $703K | — | $703K | 2.0% |
| Year 1 | $724K | +$1.2M | $1.9M | 5.6% |
| Year 2 | $745K | +$1.8M | $2.6M | 7.4% |
| Year 3 | $768K | +$1.8M | $2.6M | 7.5% |
| Year 4 | $791K | +$1.8M | $2.6M | 7.6% |
| Year 5 | $814K | +$1.8M | $2.6M | 7.6% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $344K | $516K | $689K | $826K |
| Denial Rate Reductio | $341K | $511K | $682K | $818K |
| A/R Days Reduction | $209K | $314K | $419K | $503K |
| Clean Claim Rate | $11K | $17K | $22K | $26K |
| Total | $906K | $1.4M | $1.8M | $2.2M |
Peer Context — Where This Hospital Sits
Key metrics vs 17 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 2.0% | -17.9% | 2.0% | 6.8% | P47 |
| Net-to-Gross | 17.9% | 22.8% | 46.5% | 55.9% | P12 |
| Occupancy | 41.8% | 23.4% | 41.8% | 60.6% | P47 |
| Rev/Bed | $1.4M | $479K | $1.1M | $1.4M | P59 |
| Exp/Bed | $1.3M | $454K | $1.3M | $1.7M | P53 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.